The Food and Drug Administration yesterday approved Digene Corp.'s two-in-one test for cervical cancer as a primary screening tool, giving what was a follow-up examination the same commercial status ...
A federal advisory panel approved it. The American Cancer Society said it was "promising." An editorial in the New England Journal of Medicine urged its adoption. But the biggest test of Digene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results